Wells Fargo
BTTX

Wells Fargo’s Better Therapeutics, Inc. Common Stock BTTX Stock Holding History

Wells Fargo’s Portfolio BTTX Stock Details BTTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-179
Closed -$35 – 7769
2023
Q4 		$35 Buy
179
+58
+48% +$13 ﹤0.01% 7034
2023
Q3 		$44 Buy
121
+4
+3% +$3 ﹤0.01% 6956
2023
Q2 		$126 Buy
117
+60
+105% +$58 ﹤0.01% 6824
2023
Q1 		$40 Hold
57
– – ﹤0.01% 7174
2022
Q4 		$63 Buy
57
+2
+4% +$3 ﹤0.01% 6936
2022
Q3 		$0 Sell
55
-10
-15% -$18 ﹤0.01% 7633
2022
Q2 		$0 Buy
65
+5
+8% +$8 ﹤0.01% 7747
2022
Q1 		$0 Buy
60
+1
+2% +$3 ﹤0.01% 8080
2021
Q4 		$0 Buy
+59
New +$484 ﹤0.01% 8024

Other funds holding BTTX

CIAS
Capital Investment Advisory Services Raleigh, North Carolina $1.62B AUM 27.01% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Wells Fargo's BTTX Position: Q1 2024 in Review

Wells Fargo sold out of Better Therapeutics, Inc. Common Stock (BTTX) in Q1 2024, closing a stake of 179 shares — an estimated $35 sold.

Wells Fargo first reported a position in BTTX in Q4 2021 and held it in 9 quarters. The position peaked at $126 in Q2 2023. 3 funds tracked by Wall St. Rank hold BTTX as of Q1 2024.

  • Wells Fargo reported no remaining Better Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 179 Better Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $35.
  • Wells Fargo first reported a position in Better Therapeutics, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
  • Wells Fargo's Better Therapeutics, Inc. Common Stock position peaked at $126 in Q2 2023.
  • 3 funds tracked by Wall St. Rank held Better Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.